|
1）Bullinger L, Dohner K, Bair E, et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med. 2004; 350: 1605-16
|
|
|
|
2）Marcucci G, Radmacher MD, Maharry K, et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008; 358: 1919-28
|
|
|
|
|
|
3）Frohling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002; 100: 4372-80
|
|
|
|
|
|
4）Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008; 358: 1909-18
|
|
|
|
|
|
5）Frohling S, Schlenk RF, Stolze I, et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol. 2004; 22: 624-33
|
|
|
|
|
|
6）Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of pre-remission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000; 96: 4075-83
|
|
|
|
|
|
7）Byrd JC, Mrozek K, Dodge RK, et al. Pre-treatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002; 100: 4325-36
|
|
|
|
|
|
8）Swerdlow S, Campo E, Harris N, et al. In: World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haemato-poietic and Lymphoid Tissues. Lyon: IARC; 2008
|
|
|
|
|
|
9）Akagi T, Ogawa S, Dugas M, et al. Frequent genomic abnormalities in acute myeloid leukemia/myelodysplastic syndrome with normal karyotype. Haematologica. 2009; 94: 213-23
|
|
|
|
|
|
10）Walter MJ, Payton JE, Ries RE, et al. Acquired copy number alterations in adult acute myeloid leukemia genomes. Proc Natl Acad Sci U S A. 2009; 106: 12950-5
|
|
|
|
|
|
11）Gilliland DG. Hematologic malignancies. Curr Opin Hematol. 2001; 8: 189-91
|
|
|
|
|
|
12）Ley TJ, Mardis ER, Ding L, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature. 2008; 456: 66-72
|
|
|
|
|
|
13）Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009; 361: 1058-66
|
|
|
|
|
|
14）Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010; 363: 2424-33
|
|
|
|
|
|
15）Yan XJ, Xu J, Gu ZH, et al. Exome sequencing identifies somatic mutations of DNA methyl-transferase gene DNMT3A in acute monocytic leukemia. Nat Genet. 2011; 43: 309-15
|
|
|
|
|
|
16）Grossmann V, Tiacci E, Holmes AB, et al. Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. Blood. 2011; 118: 6153-63
|
|
|
|
|
|
17）Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leu-kemia. Cell. 2012; 150: 264-78
|
|
|
|
|
|
18）Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012; 481: 506-10
|
|
|
|
|
|
19）Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblas-toma multiforme. Science. 2008; 321: 1807-12
|
|
|
|
|
|
20）Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009; 360: 765-73
|
|
|
|
|
|
21）Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differen-tiation. Cancer Cell. 2010; 18: 553-67
|
|
|
|
|
|
22）Nasmyth K, Haering CH. Cohesin: its roles and mechanisms. Annu Rev Genet. 2009; 43: 525-58
|
|
|
|
|
|
23）Krantz ID, McCallum J, DeScipio C, et al. Cornelia de Lange syndrome is caused by mutations in NIPBL, the human homolog of Drosophila melanogaster Nipped-B. Nat Genet. 2004; 36: 631-5
|
|
|
|
|
|
24）Bose T, Gerton JL. Cohesinopathies, gene expression, and chromatin organization. J Cell Biol. 2010; 189: 201-10
|
|
|
|
|
|
25）Solomon DA, Kim T, Diaz-Martinez LA, et al. Mutational inactivation of STAG2 causes aneu-ploidy in human cancer. Science. 2011; 333: 1039-43
|
|
|
|
|
|
26）Wendt KS, Yoshida K, Itoh T, et al. Cohesin mediates transcriptional insulation by CCCTC-binding factor. Nature. 2008; 451: 796-801
|
|
|
|
|
|
27）Parelho V, Hadjur S, Spivakov M, et al. Cohesins functionally associate with CTCF on mammalian chromosome arms. Cell. 2008; 132: 422-33
|
|
|
|
|
|
28）Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005; 352: 254-66
|
|
|
|
|
|
29）Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010; 115: 453-74
|
|
|
|
|
|
30）Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012; 366: 1079-89
|
|
|
|
|
|
31）Garaj S, Hubbard W, Reina A, et al. Graphene as a subnanometre trans-electrode membrane. Nature. 2010; 467: 190-3
|
|
|
|
|